StockData

IRulya Therapeutics Inc. (IRLA) bonds

IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$38.45+1.09 (+2.92%)

Close on Nov 17, 2026Market cap $39.11MP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

IRulya Therapeutics reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

When the debt comes due

Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2025

From the debt maturity table in the annual report (filing). “Later” is everything due after year five.

Notes and loans outstanding

As tagged in IRulya Therapeutics's 10-Q for the period ended Oct 20, 2023

IRulya Therapeutics's filings do not break debt down by note

The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed. The repayment schedule above comes from the same report.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySizeDrawn
EIB Loan ,Tranche D€10.00M–
EIB Loan Tranche C€10.00M–
EIB Loan, Tranche A€3.00M–
EIB Loan, Tranche B€7.00M–
European Investment Bank Loan€30.00M€10.00M

See a number that looks wrong?